In the present study, data from a large cohort of gliomas (n = 592) were used to corroborate previous findings on the 5 glioma molecular groups defined by three robust markers, 1p/19q codeletion, IDH mutations, and TERT promoter mutations [2] and to demonstrate, for lower-grade gliomas, the differential prognostic value of hematological markers in each molecular group. This evidence concerns the gene IDH1 and glioma.